Background and Purpose: The diverse causes of right-sided heart failure (RHF) include,
among others, primary cardiomyopathies with right ventricular (RV) involvement, RV …

Despite the advancement in medicine, management of heart failure (HF), which usually
presents as a disease syndrome, has been a challenge to healthcare providers. This is …

Background COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has
significant protective benefits for the heart and kidney. We aimed to see whether this agent …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

GPCRs (G-protein [guanine nucleotide-binding protein]–coupled receptors) play a central
physiological role in the regulation of cardiac function in both health and disease and thus …

Background Specialised disease management programmes for heart failure aim to improve
care, clinical outcomes and/or reduce healthcare utilisation. Since the last version of this …

Acute decompensated heart failure (ADHF) is one of the leading admission diagnoses
worldwide, yet it is an entity with incompletely understood pathophysiology and limited …

Background In patients with acute heart failure, early intervention with an intravenous
vasodilator has been proposed as a therapeutic goal to reduce cardiac-wall stress and …

Cardiovascular disease is a major contributor to global morbidity and mortality and is the
common end point of many chronic diseases. The endothelins comprise three structurally …

Background Serelaxin, recombinant human relaxin-2, is a vasoactive peptide hormone with
many biological and haemodynamic effects. In a pilot study, serelaxin was safe and well …